Abstract:Cardioneuroablation (CNA) is currently considered as a promising treatment option for patients with symptomatic bradycardia caused by vagotonia. This study aims to further investigate its safety and efficacy in patients suffering from vagal bradycardia. A total of 60 patients with vagal bradycardia who underwent CNA in the First Affiliated Hospital of Xinjiang Medical University from November 2019 to June 2022. Preoperative atropine tests revealed abnormal vagal tone elevation in all patients. First, the electroanatomic structures of the left atrium was mapped out by using the Carto 3 system, according to the protocol of purely anatomy-guided and local fractionated intracardiac electrogram-guided CNA methods. The upper limit of ablation power of superior left ganglion (SLGP) and right anterior ganglion (RAGP) was not more than 45W with an ablation index of 450.Postoperative transesophageal cardiac electrophysiological examination was performed 1 to 3 months after surgery. The atropine test was conducted when appropriate. Twelve-lead electrocardiogram, Holter electrocardiogram, and skin sympathetic nerve activity were reviewed at 1, 3, 6 and 12 months after operation. Adverse events such as pacemaker implantation and other complications were also recorded to analyze the safety and efficacy of CNA in the treatment of vagus bradycardia. Sixty patients were enrolled in the study (38 males, mean age 36.67 ± 9.44, ranging from 18 to 50 years old). None of the patients had a vascular injury, thromboembolism, pericardial effusion, or other surgical complications. The mean heart rate, minimum heart rate, low frequency, low/high frequency, acceleration capacity of rate, and skin sympathetic nerve activity increased significantly after CNA. Conversely, SDNN, PNN50, rMSSD, high frequency, and deceleration capacity of rate values decreased after CNA (all P < 0.05). At 3 months after ablation, the average heart rate, maximum heart rate, and acceleration capacity of heart rate remained higher than those before ablation, and the deceleration capacity of heart rate remained lower than those before ablation and the above results continued to follow up for 12 months after ablation (all P < 0.05). There was no significant difference in other indicators compared with those before ablation (all P > 0.05). The remaining 81.67% (49/60) of the patients had good clinical results, with no episodes of arrhythmia during follow-up. CNA may be a safe and effective treatment for vagal-induced bradycardia, subject to confirmation by larger multicenter trials.

The benefit of cardioneuroablation to reduce syncope recurrence in vasovagal syncope patients: a case-control study

Cardioneuroablation for Cardioinhibitory Vasovagal Syncope: Rationale, Approaches, and Its Role in Long-Term Management

Cardioneuroablation in Patients with Vasovagal Syncope:An updated systematic review and meta-analysis

Selective Anatomical Catheter Ablation of Left Atrial Ganglionated Plexus for Vasovagal Syncope: Left Superior and Right Anterior Ganglionated Plexus Ablation

Cardioneuroablation for the management of patients with recurrent vasovagal syncope and symptomatic bradyarrhythmias: the CNA-FWRD Registry

Effectiveness of cardioneuroablation in different subtypes of vasovagal syncope

Cardioneuroablation as a strategy to prevent pacemaker implantation in young patients with vasovagal syncope

Long‐term outcomes of cardioneuroablation with and without extra‐cardiac vagal stimulation confirmation in severe cardioinhibitory neurocardiogenic syncope

Cardioneuroablation for Treating Vasovagal Syncope: Current Status and Future Directions

Potential consequences of cardioneuroablation for vasovagal syncope: A call for appropriately designed, sham-controlled clinical trials

Cardioneuroablation for vasovagal syncope: insights on patients' selection, centre settings, procedural workflow and endpoints-results from an European Heart Rhythm Association survey

Cardioneuroablation for reflex asystolic syncope: Mid-term safety, efficacy, and patient's acceptance

Simplified Cardioneuroablation in the Treatment of Reflex Syncope, Functional AV Block, and Sinus Node Dysfunction

Cardioneuroablation: the known and the unknown

Long-Term Evaluation of the Vagal Denervation by Cardioneuroablation using Holter and Heart Rate Variability

Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (brugada Ablation of VF Substrate Ongoing Multicenter Registry).

Safety and efficacy of cardioneuroablation for vagal bradycardia in a single arm prospective study

Cardioneuroablation for the treatment of carotid sinus syndrome

Cardioneuroablation for the management of neurally mediated syncope, sinus bradycardia, and atrioventricular block

Cryoballoon cardioneuroablation: New electrophysiological insights